drugset / Trial / NCT06156267
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
Phase 0
Not yet recruiting
30 enrolled
Fudan University
Shanghai Regenelead Therapies Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase 1, open-label study to evaluate the safety and tolerability of neoantigen personalized mRNA tumour vaccine combined with Adebrelimab (a PD-L1 humanized monoclonal antibody) in patients with surgically resected pancreatic adenocarcinoma.
Timeline
- Start
- 2024-01
- Primary completion
- 2026-04
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | mRNA tumor vaccines | Messenger RNA (mRNA) | — | — |